1,109 results match your criteria Nephrogenic Systemic Fibrosis


Safety and Gadolinium Distribution of the New High-Relaxivity Gadolinium Chelate Gadopiclenol in a Rat Model of Severe Renal Failure.

Invest Radiol 2021 Jun 4. Epub 2021 Jun 4.

From the Research and Innovation Department, Guerbet, Aulnay-sous-Bois, France.

Objective: The aim of this study was to investigate the toxicological profile of gadopiclenol, a new high-relaxivity macrocyclic gadolinium-based contrast agent (GBCA), in renally impaired rats, in comparison with 2 other macrocyclic GBCAs, gadoterate meglumine and gadobutrol, and 1 linear and nonionic GBCA, gadodiamide.

Methods: Renal failure was induced by adding 0.75% wt/wt adenine to the diet for 3 weeks. Read More

View Article and Full-Text PDF

Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: In Training.

Radiology 2021 Jun 1:210044. Epub 2021 Jun 1.

From the Department of Radiology, McMaster University, 1280 Main St W, Hamilton, ON, Canada L8S 4L8 (M.A.); and Departments of Radiology and Urology, Michigan Medicine, Ann Arbor, Mich (M.S.D.).

A 66-year-old male patient with end-stage chronic kidney disease undergoing maintenance dialysis and with a history of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clinical and pathologic findings consistent with nephrogenic systemic fibrosis. A summary of the evidence and recommendations for use of intravenous GBCM in patients with kidney disease is presented. © RSNA, 2021. Read More

View Article and Full-Text PDF

Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families.

Pediatr Radiol 2021 May 12. Epub 2021 May 12.

Department of Radiology, Seattle Children's Hospital, M/S MA.7.220, P.O. Box 5731, Seattle, WA, 98145-5005, USA.

Gadolinium retention in the brain and other organs has recently been identified by imaging and confirmed histologically. No direct clinical effects of gadolinium retention, which occurs after gadolinium-based contrast agent (GBCA) administration for MRI, have been scientifically accepted at this time. However, there is understandable concern among medical professionals and the public about the potential effects of gadolinium retention, particularly in the brain. Read More

View Article and Full-Text PDF

Literature Commentary.

Authors:

J Neuroophthalmol 2020 Sep;40(3):434-441

In this issue of Journal of Neuro-Ophthalmology, M. Tariq Bhatti, MD, and Mark L. Moster, MD will discuss the following 6 articles: Powell G, Derry-Sumner H, Rajenderkumar D, Rushton SK, Sumner P. Read More

View Article and Full-Text PDF
September 2020

Anticoagulation in a Patient With Mechanical Prosthetic Valves and Calcific Uremic Arteriolopathy on Warfarin.

Cureus 2021 Mar 30;13(3):e14196. Epub 2021 Mar 30.

Cardiology, University of Kentucky, Bowling Green, USA.

Calciphylaxis, or calcific uremic arteriolopathy (CUA), is a rare vascular calcific disease that is most often associated with renal dysfunction and warfarin, particularly end-stage renal disease (ESRD). This condition causes debilitatingly painful skin lesions, oftentimes plaques, throughout areas of cutaneous and subcutaneous adiposity. The progression of these lesions to black eschar with ulceration is the hallmark of CUA. Read More

View Article and Full-Text PDF

Extracorporeal photopheresis and its role in heart transplant rejection: prophylaxis and treatment.

Clin Transplant 2021 Apr 29:e14333. Epub 2021 Apr 29.

Division of Cardiology, Department of Medicine, Columbia University, New York, NY, USA.

Heart transplantation is the gold standard therapeutic option for select patients with end-stage heart failure. Unfortunately, successful long-term outcomes of heart transplantation can be hindered by immune-mediated rejection of the cardiac allograft, specifically acute cellular rejection, antibody-mediated rejection, and cardiac allograft vasculopathy. Extracorporeal photopheresis is a cellular immunotherapy that involves the collection and treatment of white blood cells contained in the buffy coat with a photoactive psoralen compound, 8-methoxy psoralen, and subsequent irradiation with ultraviolet A light. Read More

View Article and Full-Text PDF

Biocompatible BSA-MnO nanoparticles for timely permeability imaging of blood-brain barrier and prediction of hemorrhage transformation in acute ischemic stroke.

Nanoscale 2021 May;13(18):8531-8542

Department of Radiology, Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China.

Hemorrhage transformation (HT) is a frequent but maybe fatal complication following acute ischemic stroke due to severe damage of the blood-brain barrier (BBB). Quantitative BBB permeability imaging is a promising method to predict HT in stroke patients for a favorable prognosis. However, clinical gadolinium chelate-based magnetic resonance (MR) imaging of the stroke suffers from a relatively low sensitivity and potential side effects of nephrogenic systemic fibrosis and intracranial gadolinium deposition. Read More

View Article and Full-Text PDF

Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Pediatr Radiol 2021 May 19;51(5):736-747. Epub 2021 Apr 19.

Department of Diagnostic Imaging, The Hospital for Sick Children, Toronto, ON, Canada.

Gadolinium-based contrast agents (GBCAs) have been used to improve image quality of MRI examinations for decades and have an excellent overall safety record. However, there are well-documented risks associated with GBCAs and our understanding and management of these risks continue to evolve. The purpose of this review is to discuss the safety of GBCAs used in MRI in adult and pediatric populations. Read More

View Article and Full-Text PDF

Gadoxetate Disodium-Enhanced Imaging of Gradenigo Syndrome in End-Stage Renal Disease.

J Neuroophthalmol 2021 Apr 1. Epub 2021 Apr 1.

Departments of Ophthalmology and Visual Neurosciences (VS, MSL, CMM) and Radiology (MG), University of Minnesota, Minneapolis, Minnesota.

Abstract: A 65-year-old man with end-stage renal disease on peritoneal dialysis was admitted for new onset binocular double vision, failure to thrive, and debilitating right-sided headaches. Medical history was significant for tympanomastoidectomy for polymicrobial mastoiditis and treatment with IV antibiotics. MRI brain without contrast was read by radiology initially as showing expected postsurgical changes; however, given patient's history of mastoiditis infection, there was a high clinical suspicion for Gradenigo syndrome. Read More

View Article and Full-Text PDF

Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.

Int J Environ Res Public Health 2021 03 15;18(6). Epub 2021 Mar 15.

Department of Internal and Pediatric Nursing, Faculty of Health Sciences, Medical University of Gdańsk, Dębinki 7, 80-211 Gdańsk, Poland.

: Nephrogenic systemic fibrosis (NFS) is a generalized disorder occurring in people with kidney failure. This new disease entity can lead to significant disability or even death. Gadolinium-associated systemic fibrosis is related to exposure to contrast agents used for magnetic resonance imaging. Read More

View Article and Full-Text PDF

Dynamic Contrast Enhanced-MR CEST Urography: An Emerging Tool in the Diagnosis and Management of Upper Urinary Tract Obstruction.

Tomography 2021 Mar 2;7(1):80-94. Epub 2021 Mar 2.

The Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205, USA.

Upper urinary tract obstructions (UTOs) are blockages that inhibit the flow of urine through its normal course, leading to impaired kidney function. Imaging plays a significant role in the initial diagnosis of UTO, with anatomic imaging (primarily ultrasound (US) and non-contrast computed tomography (CT)) serving as screening tools for the detection of the dilation of the urinary collecting systems (i.e. Read More

View Article and Full-Text PDF

The Use of Contrast Agents in Interventional Pain Procedures: A Multispecialty and Multisociety Practice Advisory on Nephrogenic Systemic Fibrosis, Gadolinium Deposition in the Brain, Encephalopathy After Unintentional Intrathecal Gadolinium Injection, and Hypersensitivity Reactions.

Anesth Analg 2021 Mar 23. Epub 2021 Mar 23.

Department of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

This Practice Advisory presents a comprehensive and evidence-based set of position statements and recommendations for the use of contrast media in interventional pain procedures. The advisory was established by an international panel of experts under the auspices of 11 multinational and multispecialty organizations based on a comprehensive review of the literature up to December 31, 2019. The advisory discusses the risks of using gadolinium-based contrast agents. Read More

View Article and Full-Text PDF

Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Abdom Radiol (NY) 2021 Mar 20. Epub 2021 Mar 20.

Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou and Chang Gung University, 5, Fu-Hsing Street, Gueishan, Taoyuan, 333, Taiwan.

Purpose: To assess the risk of nephrogenic systemic fibrosis (NSF) in patients with renal impairment undergoing gadoxetic acid-enhanced magnetic resonance imaging.

Methods: This retrospective study included patients who had an estimated glomerular filtration rate (eGFR) below 60 mL/min per 1.73 m or had undergone dialysis around the time of gadoxetic acid exposure from January 2010 to November 2019. Read More

View Article and Full-Text PDF

Mn Complexes with Pyclen-Based Derivatives as Contrast Agents for Magnetic Resonance Imaging: Synthesis and Relaxometry Characterization.

Inorg Chem 2021 Mar 24;60(6):3604-3619. Epub 2021 Feb 24.

General, Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons, 7000 Mons, Belgium.

Magnetic resonance imaging (MRI) has a leading place in medicine as an imaging tool of high resolution for anatomical studies and diagnosis of diseases, in particular for soft tissues that cannot be accessible by other modalities. Many research works are thus focused on improving the images obtained with MRI. This technique has indeed poor sensitivity, which can be compensated by using a contrast agent (CA). Read More

View Article and Full-Text PDF

Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.

Am J Physiol Renal Physiol 2021 04 22;320(4):F617-F627. Epub 2021 Feb 22.

Kidney Institute of New Mexico, University of New Mexico Health Science Center, Albuquerque, New Mexico.

Dozens of millions of people are exposed to gadolinium-based contrast agents annually for enhanced magnetic resonance imaging. Gadolinium-based contrast agents are known nephrotoxins and can trigger the potentially fatal condition of systemic fibrosis. Risk factors are practically entirely undefined. Read More

View Article and Full-Text PDF

Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Kidney Med 2021 Jan-Feb;3(1):142-150. Epub 2020 Nov 10.

American College of Radiology, Reston, VA.

Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m; upper bounds of the 95% confidence intervals: 0. Read More

View Article and Full-Text PDF
November 2020

Iron(III)-tCDTA derivatives as MRI contrast agents: Increased T relaxivities at higher magnetic field strength and pH sensing.

Magn Reson Med 2021 06 4;85(6):3370-3382. Epub 2021 Feb 4.

Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Purpose: Low molecular weight iron(III) complex-based contrast agents (IBCA) including iron(III) trans-cyclohexane diamine tetraacetic acid [Fe(tCDTA)] could serve as alternatives to gadolinium-based contrast agents in MRI. In search for IBCA with enhanced properties, we synthesized derivatives of [Fe(tCDTA)] and compared their contrast effects.

Methods: Trans-cyclohexane diamine tetraacetic acid (tCDTA) was chemically modified in 2 steps: first the monoanhydride of Trans-cyclohexane diamine tetraacetic acid was generated, and then it was coupled to amines in the second step. Read More

View Article and Full-Text PDF

Gadolinium-Based Contrast Media Nephrotoxicity in Kidney Impairment: The Physio-Pathological Conditions for the Perfect Murder.

J Clin Med 2021 Jan 13;10(2). Epub 2021 Jan 13.

Department of Surgery, Oncology, and Gastroenterology, Urology Clinic University of Padua, 35124 Padova, Italy.

Gadolinium-based contrast media (GBCM) toxicity in patients with kidney disease is a concern for the possible development of systemic nephrogenic fibrosis and possible renal complications. This review focuses on the pathological mechanisms underlying the potential kidney toxicity of gadolinium. Gadolinium, as a free compound (Gd3+), is highly toxic in humans because it competes with divalent calcium (Ca2+) and magnesium (Mg2+) ions, interfering in some relevant biologic processes. Read More

View Article and Full-Text PDF
January 2021

Diagnostic Imaging: Appropriate and Safe Use.

Am Fam Physician 2021 01;103(1):42-50

Naval Health Clinic Lemoore, Lemoore, CA, USA.

The use of diagnostic radiography has doubled in the past two decades. Image Gently (children) and Image Wisely (adults) are multidisciplinary initiatives that seek to reduce radiation exposure by eliminating unnecessary procedures and offering best practices. Patients with an estimated glomerular filtration rate less than 30 mL per minute per 1. Read More

View Article and Full-Text PDF
January 2021

Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.

Rofo 2020 Dec 21. Epub 2020 Dec 21.

Institute of Radiology, University Medical Center, Erlangen, Germany.

Background:  Radiologists have been administering gadolinium-based contrast agents (GBCA) in magnetic resonance imaging for several decades, so that there is abundant experience with these agents regarding allergic-like reactions, nephrogenic systemic fibrosis (NSF) and gadolinium retention in the brain.

Methods:  This review is based on a selective literature search and reflects the current state of research on acute adverse effects of GBCA, NSF and brain retention of gadolinium.

Results:  Due to the frequent use of GBCA, data on adverse effects of these compounds are available in large collectives. Read More

View Article and Full-Text PDF
December 2020

Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks.

Molecules 2020 Dec 7;25(23). Epub 2020 Dec 7.

Department of Biological Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada.

Gadolinium (Gd)-containing chelates have been established as diagnostics tools. However, extensive use in magnetic resonance imaging has led to increased Gd levels in industrialized parts of the world, adding to natural occurrence and causing environmental and health concerns. A vast amount of data shows that metal may accumulate in the human body and its deposition has been detected in organs such as brain and liver. Read More

View Article and Full-Text PDF
December 2020

Folic acid-appended galactoxyloglucan-capped iron oxide nanoparticles as a biocompatible nanotheranostic agent for tumor-targeted delivery of doxorubicin.

Int J Biol Macromol 2021 Jan 2;168:130-142. Epub 2020 Dec 2.

Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (Research Centre, University of Kerala), Thiruvananthapuram 695011, Kerala, India. Electronic address:

Iron oxide nanoparticles (IONPs) are employed as MRI contrast agents and as effective drug delivery vehicles. However, the limited solubility and biodegradability of these nanoparticles need to be improved for safer biomedical applications. In an attempt to improve the bottlenecks associated with IONPs, the current study focuses on the synthesis of folic acid conjugated, galactoxyloglucan-iron oxide nanoparticles (FAPIONPs), for the loading and controlled release of the encapsulated chemotherapeutic agent doxorubicin (DOX). Read More

View Article and Full-Text PDF
January 2021

Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Radiology 2021 01 10;298(1):28-35. Epub 2020 Nov 10.

From the American College of Radiology, Reston, Va (J.C.W., C.L.W., R.J.M., J.R.D., M.S.D.); National Kidney Foundation, New York, NY (R.A.R., J.Y., D.F., M.A.P.); Department of Radiology and Biomedical Imaging (J.C.W.) and Department of Internal Medicine, Section of Nephrology (M.A.P.), Yale University School of Medicine, New Haven, Conn; Department of Nephrology, Rush University Medical Center, Chicago, Ill (R.A.R.); Department of Nephrology, Henry Ford Health System, Detroit, Mich (J.Y.); Department of Radiology, University of Washington, Seattle, Wash (C.L.W.); Department of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Md (D.F.); Department of Radiology, Mayo Clinic, Rochester, Minn (R.J.M.); Department of Radiology, Cincinnati Children's Hospital Medical Center at University of Cincinnati College of Medicine, Cincinnati, Ohio (J.R.D.); Departments of Radiology (M.S.D.) and Urology (M.S.D.), Michigan Medicine, 1500 E Medical Center Dr, Room B2 A209P, Ann Arbor, MI 48109-5030; and Michigan Radiology Quality Collaborative, Ann Arbor, Mich (M.S.D.).

Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) and the National Kidney Foundation to improve and standardize the care of patients with kidney disease who have indication(s) to receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM). The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM in patients with advanced kidney disease is thought to be very low (zero events following 4931 administrations to patients with estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m; upper bounds of the 95% confidence intervals: 0. Read More

View Article and Full-Text PDF
January 2021

Contrast media in patients with kidney disease: An update.

Cleve Clin J Med 2020 11 2;87(11):683-694. Epub 2020 Nov 2.

Director, Center for Chronic Kidney Disease, Department of Nephrology and Hypertension, Cleveland Clinic; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.

Concern for contrast-induced acute kidney injury (CI-AKI) or nephrogenic systemic fibrosis may lead to withholding important studies from patients with kidney disease. However, the actual risk or even the existence of these conditions has recently been called into question. The truth probably lies somewhere in the middle. Read More

View Article and Full-Text PDF
November 2020

Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis.

Semin Arthritis Rheum 2020 12 19;50(6):1226-1237. Epub 2020 Sep 19.

Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, United States.

Numerous drugs and chemical substances are capable of inducing exaggerated tissue fibrotic responses. The vast majority of these agents cause localized fibrotic tissue reactions or fibrosis confined to specific organs. Although much less frequent, chemically-induced systemic fibrotic disorders have been described, sometimes occurring as temporally confined outbreaks. Read More

View Article and Full-Text PDF
December 2020

MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.

Magn Reson Imaging Clin N Am 2020 Nov;28(4):497-507

Department of Radiology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. Read More

View Article and Full-Text PDF
November 2020

Risk of Nephrogenic Systemic Fibrosis from Gadoxetic Acid in Patients with Severe Kidney Disease.

Radiology 2020 12 29;297(3):563-564. Epub 2020 Sep 29.

From the Department of Radiology, Michigan Medicine, University of Michigan, 1500 E Medical Center Dr, Room B2 A209A, Ann Arbor, MI 48109-5030.

View Article and Full-Text PDF
December 2020

No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.

Radiology 2020 12 29;297(3):556-562. Epub 2020 Sep 29.

From the Departments of Radiology (J.S., R.J.B., E.A.S., S.B.R.), Obstetrics and Gynecology (E.A.S.), Medical Physics (S.B.R.), Biomedical Engineering (S.B.R.), Medicine (S.B.R.), and Emergency Medicine (S.B.R.), University of Wisconsin, 600 Highland Ave, Madison, WI 53792.

Background Gadoxetic acid (GA) has distinctive pharmacokinetic properties with important applications in hepatobiliary imaging. However, there are limited data evaluating the safety of GA administration in patients with impaired kidney function and the incidence of nephrogenic systemic fibrosis (NSF). Purpose To evaluate safety of GA regarding risk of NSF in patients with impaired kidney function. Read More

View Article and Full-Text PDF
December 2020

Noncontrast Magnetic Resonance Angiography in the Era of Nephrogenic Systemic Fibrosis and Gadolinium Deposition.

J Comput Assist Tomogr 2021 Jan-Feb 01;45(1):37-51

Department of Radiology, Columbia University Medical Center, New York, NY.

Abstract: Gadolinium-based contrast agents for clinical magnetic resonance imaging are overall safe. However, the discovery of nephrogenic systemic fibrosis in patients with severe renal impairment and gadolinium deposition in patients receiving contrast have generated developments in contrast-free imaging of the vasculature, that is, noncontrast magnetic resonance angiography. This article presents an update on noncontrast magnetic resonance angiography techniques, with comparison to other imaging alternatives. Read More

View Article and Full-Text PDF
January 2021